Geron Corp. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp.

GERN 1.145

+2.2%

3:08 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: LJM	5/14/2008 3:04:29 PM
	Read Replies (1) of 3576

Geron Given FDA Hold (GERN) Geron Corporation (NASDAQ: GERN) announced today that the company received a verbal notice from the FDA that Geron's Investigational New Drug (IND) submission for GRNOPC1, its cell therapy for spinal cord injury, has been placed on clinical hold. This is an order that the FDA issues to a company to delay a proposed trial or to suspend an ongoing investigation. As the company has not seen the reasons for the hold in writing via a letter, it is unable to comment specifically. The company said in the release that it has been in communications with the FDA for 4 years leading to its filing. NASDAQ halted trading of the stock at 14:30:29 pending news, so it is now not trading. Shares did manage to trade down almost 4% to $4.71 before this halt took effect. Geron's market cap was almost $367 million before the halt, and its 52-week trading range was $3.97 to $9.85. Jon C. Ogg May 14, 2008

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next